Preparation for treatment of bacterial vaginitis, method for its preparing and method for treatment of bacterial vaginitis

FIELD: medicine, gynecology, pharmacology, pharmaceutical industry.

SUBSTANCE: invention proposes a preparation that comprises bacterial mass of live microorganisms as an active component, protecting medium and fat base. The preparation comprises lactobacilli as bacterial mass and one or some eubiotic microorganisms taken among the following group: bifidobacteria, streptococci and lactococci taken in the amount per a single dose. Also, the preparation comprises additionally an acceptable sorbent and a biologically active supplement. Also, invention relates to a method for preparing this preparation that involves preparing firstly lactobacilli bacterial mass and one or some genus of eubiotic microorganisms taken among the following group: bifidobacteria, streptococci and lactococci. Then the prepared bacterial mass of microorganisms is immobilized on sorbent used in medicine in its ratio to bacterial mass of microorganisms = (9-1):(1-9) followed by addition of the protecting medium and biologically active supplement to formed mass in the necessary amount. Also, invention describes a method for prophylaxis and treatment of bacterial vaginitis that involves intravaginal administration of the preparation described above in the amount 1-3 doses, 1-3 times per 24 h. The treatment course is prescribed individually. Invention provides expanding assortment of agents used for treatment of bacterial vaginitis. Invention can be used in obstetric-gynecological practice.

EFFECT: improved method for vaginitis treatment, valuable medicinal properties of preparation.

13 cl, 4 tbl, 1 ex

 

The invention relates to medicine, namely to pharmacology, in particular drugs for the treatment of bacterial vaginosis, and can be used in the pharmaceutical industry and obstetric practice.

Currently, the disease caused genital infections are among the most frequent gynecological diseases. In recent years there has been a growth trend of diseases associated with disruption of the normal microflora of the vagina, in particular bacterial vaginosis.

In medical practice for the treatment of diseases such widely used antimicrobial drugs, such as antibiotics. However, they are common toxic, are not always effective, in addition, cause the emergence of microorganisms resistant to the action used antibacterial agents. As a result of treatment these drugs require additional restoration of microflora of the vaginal mucosa.

In connection with the foregoing very important role for the search of new, safe and without contraindications drugs for the treatment of diseases of the vagina, accompanied by violation of microbiocenosis.

Closest to the claimed solution is a drug for the treatment of bacterial vaginosis “Lactobacterin in suppositories” (instruction to parimenti of Lactobacterin in suppositories. Nizhny Novgorod state enterprise for production of bacterial preparations. Approved by the Ministry of zdravohraneniya the USSR, November 29, 1992).

“Lactobacterin in suppositories” is a microbial mass of live lactobacilli, Leoville dried in an environment of cultivation. In addition, it contains Saharsa-relationality ingredient, which is a protective environment necessary to maintain the viability of the bacteria, and acceptable fat basis.

Living microbial cells (MC) of lactobacilli possess antagonistic activity against test strains of pathogenic and conditionally pathogenic bacteria, including Shigella, enteropathogenic E. coli, Staphylococcus, Proteus, and this determines the action of known drug in abnormal bacteriocins. Drug-prototype has a shelf life of 1 year, provided it is stored at a temperature of (4±2)°C.

However, the lack of Lactobacterin in suppositories” is not sufficiently high pharmacological properties, because they are not always antagonistic, anti-infective effects and the necessary level of engraftment of microorganisms on the vaginal mucosa. And, in addition, the drug does not have sufficient bioavailability. These disadvantages are the reason for the relatively low therapeutic e is the efficiency of the drug.

Another significant disadvantage of the drug is the lack of persistence MK under normal conditions outside the cold chain.

The present invention is the creation of a drug for treatment of bacterial vaginosis by combining ingredients in its composition, which results in high viability alive MK and as a consequence of increasing therapeutic efficacy and increase the shelf life of the drug.

The problem is solved in that the drug for the treatment of bacterial vaginosis, containing as active principle microbial mass of live bacteria, a protective environment, a fat basis, according to the invention as microbial mass contains lactobacilli and one or more delivery abioticheskikh bacteria selected from the group: bifidobacteria, streptococci and lactococcal in the amount of 105-109MK per dose, further comprises an acceptable sorbent at a ratio of it to the microbial mass of bacteria (9-1):(1-9), biologically active additive in the amount of 0.05-3.0 wt.% relative to the weight of the final product, and as a fatty basis - any reasonable basis, containing not more than 5 wt.% water and having a pH of 4,5-7,0.

Proposed by the authors of microorganisms in the composition of the proposed drug, are representative of normal microparasites vagina and cover a range of bacteria, if any amounts are experiencing certain diseases, in particular bacterial vaginosis.

A prerequisite is the presence in the preparation of lactobacilli, as they overwhelmingly determine the microflora of the vaginal mucosa. As with other microorganisms, their presence in the product is intended to enhance the biological activity of lactobacilli.

The necessary biological activity and efficacy of the treatment is determined by viability MK, their adhesive ability and capacity for colonization. The authors of the present invention proposed a content of 105-109MK in one dose, which, on the one hand, is connected with the effectiveness of the drug, and on the other, economic expediency.

On the model of white rats, which after 24 hours after administration of the drugs was done scraping the mucous membrane of the vagina, with the introduction of 0.1 ml of a suspension of the drug consisting of immobilized Lactobacillus and neimmunizirovannah lactobacilli in the same concentrations (from 10 MC/cm3up to 1010MK/cm3), it was shown that the adhesive activity of lactobacilli in the drug reaches the maximum level of 9.1·107MC/mm2with the drug containing 109MK. The further increase in the concentration of MK does not increase the level edges is I.

The data in table 1 confirm that the most clinically effective is the drug containing from 105up to 109MK in one dose.

For comparison it is shown that neemalirovannuyu bacteria inferior in adhesion to the mucosal surface, not exceeding 3,5·104MC/mm2.

Table 1

Adhesive activity of lactobacilli in the inventive preparation and lactobacilli in suspension
LactobacilliThe initial concentration of the input MK 1 cm3suspension
1021041051061081091010
Immobilized sorbent in the composition of the proposed drugThe adhesive activity of the epithelium
1,2·102,6·1022,8,0·1033,8·1046,6·1069,1·1079,2·107
Not immobilized in the composition suspensionNo1,7·1021,7·1021,7·1022,8·103 3,5·1044,1·104

Protective environment in accordance with this invention should be such that is capable of maintaining the required level viability sorbed bacteria after freeze drying.

The quantitative content of the protective environment, such as the sugar-gelatination environment, usually determined by the conditions of storage of microorganisms in the product and is 0.01-0.02% of the mass.

To an acceptable sorbents used in the inventive preparation, include any sorbents, authorized by the Ministry of health, such as derivatives of cellulose, alumina, in particular the sodium smectite and other

To achieve therapeutic efficacy of the proposed drug at the required level, you must create microcolonies consisting of particles of sorbent, which sorbed 10-40 microns. This condition, as defined in the present invention, are met by the mass ratio of sorbent to microbial mass (9-1):(1-9). Under these conditions the formation of microcolonies of bacteria will be maximum.

The particle size of the sorbent may be any suitable for the preparation of this assignment, however, the most acceptable is the size not more than 100 μm, otherwise possible mechanical irritation.

With regard to dietary supplements, t is it can have various functions.

The quantitative content of the additive is from 0.05 to 3.0 wt.% from microbial biomass of bacteria due to the fact that when the content is less than 0.05 wt.%, sharply decreases its efficiency, i.e. the impact on viability, colonization and adhesion to the mucosa MK.

With more than 3.0 wt.% the content of biologically active additives, there is a danger of lysis introduce bacteria and, in addition, possible side effects, such as irritation of the mucous from its excess, in particular, when using essential oils of plants.

The choice of ingredients biologically active additives is very wide and is caused by specific features of the proposed drug, for example, can be used fungicidal ingredients or, if necessary, the ingredients which have an antimicrobial effect, and others Introduction to the drug, for example, photoinhibition speeds up the process of colonization of the mucosa and leads to normalization of microflora on this indicator already after 48 hours.

The authors proposed as a fatty basis to use any framework suitable for cream or suppository. However, a fat basis must meet certain requirements - it should not contain more than 5% water and must provide for the preparation of pH 4,5-7,0, otherwise the viability of the bacteria drops, which sativae is located on the efficacy of the drug.

In addition, the sum of all ingredients of the proposed drug used to increase shelf and to simplify storage conditions. The results of relevant studies are shown in table 2.

Were selected for the study claimed the drugs used different sorbent and pH fat basis. Studies were conducted after a year of storage at a temperature of 22°C.

Table 2

The dependence of viability of bacteria from the pH of a fatty basis
The claimed preparation, different sorbentOriginal Qty MK 1 g medicationThe viability of bacteria, Qty MK 1 g of the drug (one year of storage)
PH fat basics
3,04,56,57,07,5
Derivatives of cellulose1,0·1091,0·1078,0·1074,0·1084,0·1085,0·107
Polymethylsiloxane1,0·1091,0·1064,0·1072,0·1073,0#x000B7; 1077,0·107
Smectite sodium1,0·1092,0·1063,0·1073,0·1085,0·1081,0·107

The data in table 2 indicate that the viability of the bacteria is highest at pH 4,5-7,0, while values below 4.5 it is not enough to achieve the desired results, and at pH values above 7.0 viability of bacteria decreases significantly.

The dependence of viability of bacteria and pH fat basis obtained after one year of storage at a temperature of 22°C indicates an increase retention while simplifying storage conditions.

To prove the clinical efficacy of the proposed drug studies have been conducted, the results of which are shown in table 3.

As the study drug was used the drug (1)corresponding to declare. As bacteria for clarity, were taken lactobacilli. Adding in accordance with the claimed solution to them bifidobacteria and/or Streptococcus, and/or lactococcal proportionally amplifies the result.

In addition, researched the drug (2) without Fyodorovka and, finally, the product (3), corresponding to the prototype.

Pointed to by the e above the drugs were injected in the vagina for women volunteers suffering from bacterial vaginosis, a pronounced decrease follow.

Table 3

Comparative characteristics of therapeutic action of the proposed drug and drug-prototype
MedicationThe content of lactobacilli in the secret of vagina, MK/cm3
Before the treatmentAfter 24 hoursAfter 48 hours
1. The product containing immobilized on alumina lactobacilli and feedbacki1,2·1032,5·1063,6·107
2. The product containing immobilized on alumina lactobacilli1,2·1033,1·1067.1·106
3. Neemalirovannuyu lactobacilli (prototype)1,2·1035,0·1064,0·104

As the results of table 3, the best clinical indicators obtained for the product (1)corresponding to declare.

Another objective of the claimed invention is to provide a method of producing drug for the treatment of bacterial vaginosis by this combination of action and modes of their OS is enforced, which allows to obtain a drug with a high therapeutic efficiency and resistance to storage under normal conditions.

The problem is solved in that in the method of producing drug for treating bacterial vaginosis, according to the invention first receives microbial mass of lactobacilli and one or more delivery abioticheskikh bacteria selected from the group of bifidobacteria, streptococcal and lactococcal, and their content in 1 g of the microbial mass is 1010-1011cells. Then the microbial mass of bacteria immobilized acceptable in medicine sorbent in its relation to microbial mass of bacteria (9-1):(1-9), then in the resulting mass of lead protective environment in the required quantity and biologically active additives in quantities of 0.05 to 3.0% relative to the weight of the final product. The resulting product is subjected to freeze drying in the mode corresponding to the kind of the used microorganisms, then dried mass is mixed with acceptable fat basis, containing less than 5% water and having a pH of 4.5-7.0 and taken in an amount corresponding to a content of 105-109MK in a single dose.

The authors stipulate that 1 g of microbial mass must contain lactobacilli and bifidobacteria, and/or streptococci, and/or the lactococcal in the amount of 1010-1011 cells.

This is because under these conditions for 1 particle sorbent must be 10-40 microns, or should be formed conglomerate, including appropriate sorbent particles and bacteria, which corresponds to a drug with useful properties. Or, in other words, from the specified microbial mass it is possible to obtain the product with 105-109MK in one dose, as shown above, in combination with other ingredients of the product meets the highest clinical efficacy.

Other conditions of the method of obtaining the drug for the treatment of bacterial vaginosis can be reduced to the following sequence of mixing of the components, which provides high viability of bacteria, sufficient colonization of the mucosa of the vagina, adhesion and high biological activity.

As to the ratio of sorbent to microbial mass, it is due to return to get effective therapeutic doses.

The method of producing drug for treating bacterial vaginosis is confirmed by the example of a specific implementation.

Example 1

Claimed the drug is produced in several stages. First get microbial mass of lactobacilli, bifidobacteria, and/or streptococcal and/or lactococcal, and their content in 1 g of microbial mass sostav the em 10 10-1011cells.

Then the obtained microbial mass immobilized on the sorbent, in particular the sodium smectite, with a particle size not exceeding 100 microns. This process is performed by thorough mixing.

The ratio of microbial biomass to the sodium smectite is 9:1.

Then the resulting mass is mixed with Saharsa-gelatination environment, taken in an amount of 0.02% with respect to the resulting mass of the drug, and from 2.5% essential oil of sage regarding the resulting weight of the preparation.

After that, the obtained product is subjected to freeze drying in trays.

The dried product is mixed with fat basis, for example, containing 90 wt.% cocoa butter and 10 wt.% lanolin, fatty basis of introducing, for example, citric acid to pH 6.5. Fatty base has a moisture content less than 5%.

The resulting mass to form suppositories weighing from 1 g to 1.5 g

Ointment get by the method described above with the difference that as a fat basis use any acceptable ointment base.

The next task of the invention is to provide a method for treatment and prevention of bacterial vaginosis by using the preparation described above, which results in high clinical effectiveness of the treatment.

The problem is solved in that way profile is Tiki and treatment of bacterial vaginosis according to the invention, intrawaginalno enter product according to claims 1 to 7, containing lactobacilli and one or more delivery abioticheskikh bacteria selected from the group: bifidobacteria, streptococci and lactococcal in the amount of 105-109living cells per dose, and the drug is administered 1-3 times daily in the amount of 1-3 doses, and the course of treatment is determined individually depending on the extent of damage to the mucous membrane of the vagina.

In the present method of treatment of bacterial vaginosis by using a preparation containing 105-109MK 1 dose and other appropriate components, defined daily intake average of 1-3 doses depending on the severity of the disease. In the case of prophylactic use of daily intake of the drug could be 1 dose.

The course of treatment is determined individually in each case depending on the objective measures of the severity of the disease and of the treatment results.

The treatment effect may be enhanced by pre-irrigation of the vagina, for example, saline or broth of herbs at pH 4.5-5.5. This procedure is appropriate, as it is aimed at mechanical removal of mucus and conditionally pathogenic microbes. After such cleaning, the access of the claimed preparation in the form of a suppository or cream to the affected mucous easier.

To the ome, an additional positive result is when the pre-treatment vaginal suspension acceptable sorbent, the role of which is to enhance the cleansing effect and preparation for mucous colonization of introduced bacteria.

In cases where along with bacterial vaginosis have comorbidities, it is possible to treat, for example, antifungicide or other drugs.

Studies have been conducted aimed at determining the microbiological effectiveness of the correction of vaginal microbiocenosis of women with symptoms of bacterial vaginosis.

Under supervision there were 19 women with symptoms of bacterial vaginosis, expressed in the reduction or absence of lactobacilli in the presence of the key cells (more than 10 in the field of view), in the amount of Gardnerella 1 g discharge more than 106in irritation.

The patients were divided into three randomized groups. Before the introduction of drugs vaginal pre-purified saline solution, driven by adding lemon juice to pH 5.0.

The first group of women intrawaginalno have introduced the claimed preparation in the form of ointments in the amount of 1 g, 2 times a day for 5 days.

The second group of women were administered a suspension of lactobacilli in physiological solution at pH 5.0 in the course is E. 5 days.

And, finally, the third group of women was the control they have introduced the ointment base of the drug within 5 days.

Criteria for positive action treatment considered:

- bringing lactobacilli to normal concentrations (1071 g of the discharge);

lack or reduction of key cells;

- reducing the population of generell to 102-3;

- stop itching.

Table 4 presents the results obtained.

Table 4

The results of treatment of patients with bacterial vaginosis
TreatmentThe number of women in groupCriteria recovery
ItchingThe number in the key cellQuantity in GardnerellaThe number of lactobacilli
The claimed preparation4NoNo102>107
Lactobacilli in suspension4+6-9>103<107
Ointment base4++10-12>107<103
Before the treatment12 +++>10>107<103

The results obtained (table 4) suggests that the application of treatment with the proposed medication after 5 days of normal vaginal microbiocenosis, which is confirmed by microbiological indicators, and one of the elements of the clinical features.

For comparison, in the treatment of a suspension of lactobacilli have shown some improvement over the study criteria, however, the normalization of microflora has not occurred.

Ointment base, compared with the original condition of the patients, there were no improvements made.

Thus, the proposed drug for the treatment of bacterial vaginosis showed high clinical characteristics, method of its production is aimed at ensuring high efficiency of the treatment. And, in addition, the composition of the drug and the characteristics of its receipt provides simplified storage conditions, with a simultaneous increase of storage time.

The method of treatment of bacterial vaginosis has been proven clinical results of the drug, which is confirmed by objective criteria healing the sick.

1. Drug for the treatment of bacterial vaginosis, containing as active principle microbial mass of live bacteria, a protective environment, a fat basis, characterized in that m is Krasnoi mass contains lactobacilli and one or more delivery abioticheskikh bacteria, selected from the group of bifidobacteria, streptococci and lactococcal in the amount of 105-109MK per dose, further comprises an acceptable sorbent when the mass ratio to the microbial mass of bacteria (9-1):(1-9), biologically active additive in the amount of 0.05-3.0 wt.% relative to the weight of the final product, and as a fatty basis - any reasonable basis, containing not more than 5 wt.% water and having a pH of 4,5-7,0.

2. The preparation according to claim 1, characterized in that the acceptable sorbent has a particle size of not more than 100 μm and has an immovable activity to MK from 10 to 100% of its surface.

3. The preparation according to claim 1 or 2, characterized in that the biological additive contains one or more ingredients that have antifungal and/or antimicrobial activity, and/or effect-enhancing activity input in the preparation of microorganisms.

4. The preparation according to claim 1, characterized in that it is a suppository or ointment.

5. The method of producing drug for treating bacterial vaginosis, characterized in that the first microbial get a lot of Lactobacillus and one or more delivery abioticheskikh bacteria selected from the group: bifidobacteria, streptococcal and lactococcal, and their content in 1 g of the microbial mass is 1010-1011cells, then the microbial mass of bacteria IMM is brisout acceptable in medicine sorbent in its relation to microbial mass of bacteria (9-1):(1-9), then the resulting mass is injected protective environment in the required quantity and biologically active additives in quantities of 0.05 to 3.0% relative to the weight of the final product, the resulting product is subjected to freeze drying in the mode corresponding to the kind of the used microorganisms, then dried mass is mixed with acceptable fat basis, containing less than 5% water and having a pH of 4.5-7.0 and taken in an amount corresponding to a content of 105-109MK in a single dose.

6. The method according to claim 5, characterized in that the use of sorbent particle size of not more than 100 microns.

7. The method according to claim 5 or 6, characterized in that the use of biologically active additives containing one or more ingredients that have antifungal and/or antimicrobial activity, and/or effect-enhancing activity input in the preparation of microorganisms.

8. The method according to claim 5, characterized in that the use of fat-based, suitable for the production of cream.

9. The method according to claim 5, characterized in that the use of fat-based, suitable for the production of suppository.

10. Method for the prevention and treatment of bacterial vaginosis, characterized in that intrawaginalno enter product according to claims 1 to 4, containing lactobacilli and one or more delivery abioticheskikh bacteria selected from the group of: Bifidobacterium, Streptococcus is in and of lactococcal in the amount of 10 5-109living cells per dose, and the drug is administered 1-3 times daily in the amount of 1-3 doses, and the course of treatment is determined individually depending on the extent of damage to the mucous membrane of the vagina.

11. The method according to claim 10, wherein the pre-irrigate the vagina with saline solution or decoction of herbs.

12. The method according to claim 10 or 11, characterized in that the pre-introduced into the vagina, the suspension is acceptable sorbent.

13. The method according to claim 10 or 11, or 12, characterized in that the pre-introduced into the vagina antifungicide medicines.



 

Same patents:

FIELD: medicine.

SUBSTANCE: the present innovation deals with medicinal preparation as an ointment for treating skin burns. The suggested preparation contains bee wax, propolis and vegetable oil. Thus, application of initially intact propolis and bee wax in combination with fatty foundation as vegetable oil enables to cheapen and simplify the technique to prepare the preparation, and optimally matched consistence provides prolonged safety of the preparation and accelerates healing of skin burns.

EFFECT: higher efficiency of therapy.

1 cl, 2 ex

FIELD: organic synthesis.

SUBSTANCE: invention provides a method for preparing water/glycerol complex of (2,3-dihydroxypropyl) ortho-titanate hydrochloride (chloride) having symbolic name "Ephtiderm", which is depicted by following empirical formula: Method consists in that glycerol is mixed with butyl ortho-titanate at molar ratio 12:1, whereupon butanol is distilled off in vacuum, residue is treated with water and aqueous hydrochloric acid to form reaction mass with pH 2.2-3.0, which is heated in vacuum. Method is characterized by that glycerol is mixed with low-grade butyl ortho-titanate and chloroform, reaction mass during the synthesis is maintained at temperature up to 100°C in vacuum 40-200 mm Hg, while chloroform is added at 40-50°C in amount corresponding to 1 L chloroform per 2 L low-grade butyl ortho-titanate.

EFFECT: reduced expenses due to use of low-grade butyl ortho-titanate and simplified technology.

1 tbl, 3 ex

Acyzol-based agent // 2247558

FIELD: pharmaceutical industry.

SUBSTANCE: invention provides novel nontoxic and highly bioavailable acyzol-based agent characterized by high activity in treatment of skin diseases, in restoration of structural skin processes, suppression of nevus pigmentosis, and flattening of folds.

EFFECT: increased assortment of skin-healing drugs.

7 cl, 4 ex

FIELD: pharmaceutical industry.

SUBSTANCE: invention provides antiinflammatory and wound-healing ointment based on natural components, which invention, along with vegetable oils, may further contain ursine fat, ursine bile, propolis, lanoline, honey, and mummified guano. Variously formulated ointments can be used for treating hemorrhoids, burns, antritis, post-stroke condition, gunshot and stab-punctured wounds, trophic ulcer, postoperative fistula, oophoritis, diabetic microangiopathy of lower extremities, as well as papillomas, birthmarks, seborrhea, and psoriasis.

EFFECT: expanded therapeutical possibilities.

6 cl, 17 ex

"antipsoriaz" cream // 2246935

FIELD: pharmaceutical industry.

SUBSTANCE: invention relates to developing medicaments in the form of ointment based on vegetable components and designed, in particular, to treat psoriasis as well as fungus diseases and can also be used in cosmetology. Psoriasis treatment cream includes water extracts of bur-marigold (Bidens tvipartita), white birch leaves (Betula alba L), greater celandine (Chelidonium majus), calendula (Calendula officanalis L), cudweed (Gnphalium uliginosum L), medical vaseline, lanolin, camphor, linseed oil, and medical solid oil at specified proportions of components.

EFFECT: increased treatment efficiency, avoided use of chemical additives, and prolonged shelf time.

FIELD: pharmaceuticals.

SUBSTANCE: invention provides topical blood circulation improving remedy containing simultaneously nitroglycerine and aminophylline. Remedy can be provided in the form of emulsion, gel, or ointment, which are administered 1-2 times a day.

EFFECT: strengthened blood circulation activation effect, which is prolonged to 24 hours.

5 cl, 9 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with curative ointments of antiphlogistic and wound-healing action and could be applied for treating hemorrhoid, burns, bruises, fractures, wounds, chronic bronchitis, polyarthritis, periarthritis, radiculitis, trophic ulcer and psoriasis. Three variants of ointments have been suggested. They contain oily extract of plant components and, also, honey, mumiye, propolis and bear oil. This innovation enables to widen the assortment of ointments of antiphlogistic and wound-healing and the range of curative action upon a body.

EFFECT: higher efficiency of application.

3 cl, 11 ex

FIELD: agriculture, animal husbandry, organic chemistry.

SUBSTANCE: antiseptic ointment comprises cationic surface-active substance, lower glycols, polyethylene glycols, water and ethylene glycol monophenolic ester and higher polyethylene glycols taken in the definite ratio of components. As cationic surface-active substance ointment comprises N-alkyl-N-alkoxycarbonylmethylhexahydroazipinium chloride or alkyldimethylbenzylammonium chloride, or cetylpyridinium bromide, or cetylpyridinium chloride, or 1,2-ethylenebis-(N-methylcarbdecyloxymethyl)ammonium dichloride, or ethylhexadecyldimethylammonium chloride, or chlorhexidine; as lower glycol ointment comprises 1,2-propylene glycol or polyethylene glycol-300, or polyethylene glycol-400; as higher polyethylene glycol ointment comprises polyethylene glycol-1500 or polyethylene glycol-3000, or polyethylene glycol-4000, or polyethylene glycol-6000. Ointment elicits the high antibacterial activity, broad spectrum of bactericidal effect and low irritating effect with respect to udder skin. Invention can be used for sanitary-hygienic treatment of udder of lactating cows for prophylaxis and rapid healing external damages of udder and nipples (arising cracks), prophylaxis of mastitis, enhancing milk purity by microbiological indices.

EFFECT: valuable antiseptic properties of ointment.

2 cl, 1 tbl, 22 ex

The invention relates to compositions and methods for the treatment and prevention of such diseases and conditions as graft rejection, surgical adhesions, inflammatory bowel disease, nasal polyps, and includes delivery to the site of inflammation antimicrotubular agent is paclitaxel, or an analogue or derivative
The invention relates to the field of pharmaceutical industry and relates to pharmaceutical compositions for the treatment of herpes virus infection

FIELD: pharmaceutical industry.

SUBSTANCE: rectal- and vaginal-administration suppositories contain 1,3-diethylbenzimidazolium triiodide as active principal, polyvinylpyrrolidone as solubilizer and stabilizer, and lipophilic base with specified proportions of components.

EFFECT: extended therapeutical activity and reduced occurrence of side effects.

4 cl, 2 ex

FIELD: chemical and pharmaceutical industry.

SUBSTANCE: the present innovation deals with creating medicinal preparations of plant origin and could be applied for treating functional constipations and affected biorhythm of defecation. It is suggested to apply either dry aqueous or aqueous-alcoholic extract of horse chestnut seeds of Aesculus species to prepare curative-prophylactic preparation in case of constipation and affected biorhythm of defecation. The suggested preparation should be applied in the form of powder, tablets or suppositories. Pharmaceutical composition for preventing and treating constipation and affected biorhythm of defecation contains an active substance out of medicinal plant and a pharmaceutically acceptable filling agent, moreover, this preparation is designed as suppositories and contains either dry aqueous or aqueous-alcoholic extract of horse chestnut seeds of Aesculus species and suppository hydrophobic foundation at certain content of ingredients. Dry aqueous or aqueous-alcoholic extract contains 1-50% active substance as escin. As foundation it could contain either cacao oil or vitepsol. The method for preventing and treating constipations and affected biorhythm of defecation deals with introducing the suggested pharmaceutical composition into patient's anus 5-15 min before planned act of defecation. Application of "Rectum-activ" preparation provides positive result at treating functional psychogenic constipation: in 5-15 min after introducing a suppository into anus pronounced urgency for defecation. In case of course therapy for 4 wk one should observe restoration of natural urgency for intestinal evacuation. Moreover, purgative preparation causes no unfavorable pain feelings.

EFFECT: higher efficiency.

10 cl, 6 ex

The invention relates to medicine and can be used in proctology, urology, obstetrics and gynecology, Pediatrics, gastroenterology, Oncology, therapy, surgery, etc

The invention relates to compositions and methods for the treatment and prevention of such diseases and conditions as graft rejection, surgical adhesions, inflammatory bowel disease, nasal polyps, and includes delivery to the site of inflammation antimicrotubular agent is paclitaxel, or an analogue or derivative
The invention relates to the field of pharmaceutics and can be used in the treatment of prostatitis
The invention relates to the field of pharmaceutical industry and relates to vaginalnyj suppositories for the treatment of imperative incontinence urination

The invention relates to the field of veterinary obstetrics

The invention relates to medicine, in particular to urology, andrology

The invention relates to the field of pharmacology and medicine

The invention relates to pharmaceutical industry

FIELD: medicinal microbiology, biotechnology.

SUBSTANCE: invention relates to a method for assay of specific activity of probiotics and industrial strains that involves determination of the amount of viable microorganisms. The level of viable microorganisms are determined by their adhesive capacity activity with respect to human erythrocytes. Method provides reducing time for assay of the specific activity up to 2-3 h and with using available reagents. Invention can be used as the express-method for estimation of the level of the specific activity (amount of live microorganisms in the preparation dose) of probiotics of different medicinal formulations (lyophilized biomass, tablet and suppository), and industrial strains by the level of their adhesive activity.

EFFECT: improved method for estimation.

3 cl, 5 tbl, 8 ex

Up!